+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Dilated Cardiomyopathy Therapeutic Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4896105
  • Report
  • January 2020
  • Region: Global
  • 112 pages
  • Mordor Intelligence
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • AstraZeneca plc.
  • Pfizer Inc.
  • t2cure GmbH
  • Vericel Corporation
  • MORE
Market Overview

The dilated cardiomyopathy therapeutics market is anticipated to grow with a CAGR of nearly 3.6% during the forecast period. The major factors attributing to the growth of the dilated cardiomyopathy therapeutics market are increasing life expectancy and increasing prevalence of heart problems. Furthermore, the increasing number of people suffering from cardiac muscle infections, along with drug or alcohol abuse are also the factors that push the growth of the market.

According to the British Heart Foundation (BHF), 17,06,213 cases of cardiovascular diseases are diagnosed in the United Kingdom alone. As per the statistics, the incidence of cardiovascular diseases is increasing which is directly proportional to the market growth. Whereas the side effects of dilated cardiomyopathy therapeutics that cause serious discomfort to the patients are restraining the market.

Scope of the Report

According to the scope of the report dilated cardiomyopathy is a heart disorder that is caused due to the enlargement of the heart. The market is segmented by Drug Class and Geography.

Key Market Trends

Outstanding clinical results and satisfactory patient compliance of Drug Class makes it suitable for the treatment of Dilated Cardiomyopathy
  • Dilated cardiomyopathy is a disease where the ability of the heart to pump blood is decreased due to the enlargement of the left ventricle.
  • The driving factors of the segment are the excellent results of the therapy and the high prevalence of heart diseases. Due to the advancements in healthcare segment, the average life expectancy of an individual is increasing, which results in the rise in the geriatric population, who are more susceptible to heart diseases.
  • According to the World Health Organization (WHO), cardiovascular diseases is the number one cause of death globally, taking an anticipated 17.9 million lives each year.
  • Therefore as the prevalence of heart diseases increases the growth of the market increases too.
North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall dilated cardiomyopathy therapeutics market, throughout the forecast period. The growth is due to the rising incidence of cardiovascular diseases, well-established insurance policies and the availability of advanced healthcare infrastructure are the major factors. In the North America region, the United States holds the largest market share due to factors such as an increasing number of geriatric populations, along with a growing number of heart diseases in the country, which is anticipated to stimulate the demand in this region. According to the American College of Cardiology (2017), Cardiovascular disease accounts for 800,000 deaths in the United States. As the number of cardiovascular diseases increases the market for dilated cardiomyopathy rises.

Competitive Landscape

The dilated cardiomyopathy therapeutics market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics, Inc, AstraZeneca plc., Vericel Corporation, Pfizer inc., t2cure GmbH, MyoKardia, and Kasiak Research pvt.ltd.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4


  • AstraZeneca plc.
  • Pfizer Inc.
  • t2cure GmbH
  • Vericel Corporation
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing prevalence of heart problems
4.2.2 Drugs and alcohol abuse
4.3 Market Restraints
4.3.1 The side effects of dilated cardiomyopathy therapeutics
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Drug Class
5.1.1 Aldosterone antagonists
5.1.2 Angiotensin-converting enzyme (ACE) inhibitors
5.1.3 Angiotensin II receptor blockers
5.1.4 Beta-blockers
5.2 Geography
5.2.1 North America United States Canada Mexico
5.2.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.2.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.2.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.2.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Zensun Shanghai Sci & Tech Co Ltd
6.1.2 Capricor Therapeutics, Inc.
6.1.3 Vericel Corporation
6.1.4 AstraZeneca plc.
6.1.5 Pfizer Inc.
6.1.6 t2cure GmbH
6.1.7 MyoKardia and Kasiak Research pvt.ltd.

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Zensun Shanghai Sci & Tech Co Ltd
  • Capricor Therapeutics, Inc.
  • Vericel Corporation
  • AstraZeneca plc.
  • Pfizer Inc.
  • t2cure GmbH
  • MyoKardia and Kasiak Research pvt.ltd.
Note: Product cover images may vary from those shown